Global Therapeutic Vaccines Market Industry: Market Size & Forecast 2026

The global therapeutic vaccines market covers a broad range of immunizations designed to treat existing conditions or provide targeted disease prevention across viral, bacterial, and oncological indications. In 2025, the market stands at approximately $50.46 billion, with expectations to reach $63.66 billion by 2030. The industry is supported by widespread vaccination programs, growing demand for advanced immunization solutions, and continued innovation in vaccine delivery mechanisms.

• •Market valued at $50.46 billion in 2025 with 4.8% projected annual growth through 2030
• •Encompasses vaccines for infectious diseases including pneumococcal infections, influenza, hepatitis, and measles-mumps-rubella (MMR)
• •Technologies include conjugate, recombinant, inactivated, live attenuated, viral vector, and mRNA platforms

Several key factors are fueling expansion across the vaccines market. Rising global disease prevalence, particularly for influenza and pneumococcal infections, increases demand for both pediatric and adult immunization programs. Advancements in vaccine technology, especially mRNA and viral vector platforms, have accelerated development timelines and improved efficacy profiles. Additionally, government and non-profit initiatives focused on expanding immunization access in emerging economies continue to broaden the market's reach.

• •Increasing incidence of infectious diseases driving demand for preventive and therapeutic immunization solutions
• •Technological innovations including mRNA and viral vector vaccines enabling faster development and broader disease coverage
• •Expanding vaccination programs and government funding supporting market growth in developing regions

The vaccines market is segmented by technology, type, route of administration, and disease indication. By technology, categories include conjugate, recombinant, inactivated, live attenuated, viral vector, and mRNA vaccines. Disease segments cover pneumococcal, influenza, hepatitis, and MMR among others, with vaccines administered through parenteral or oral routes. North America and Europe historically lead market share due to advanced healthcare infrastructure, while Asia-Pacific is expected to show the fastest growth driven by rising healthcare access and large population bases.

• •Technology segments include conjugate, recombinant, inactivated, live attenuated, viral vector, and mRNA vaccines
• •Key disease indications span pneumococcal infections, influenza, hepatitis, MMR, and other viral and bacterial diseases
• •Asia-Pacific region anticipated to register fastest growth due to expanding healthcare infrastructure and increasing immunization initiatives

What are the recent trends and outlook?

The market is moving toward more personalized and adaptable vaccine solutions, with continued expansion of mRNA technology into new disease areas beyond COVID-19. Combination vaccines that protect against multiple diseases in a single formulation are gaining traction, offering convenience and reduced administration costs. As the industry evolves toward 2030 and beyond, investments in manufacturing scalability, cold chain logistics, and global distribution networks will be critical to meeting growing worldwide demand.

• •mRNA technology platform expected to expand into new therapeutic areas including cancer and chronic infectious diseases
• •Combination and multivalent vaccines gaining adoption to reduce dosing frequency and improve patient compliance
• •Manufacturing capacity expansion and supply chain strengthening prioritized to support projected market growth through 2030 and beyond